Endometrial cancer in premenopausal women 45 years and younger

https://doi.org/10.1016/0029-7844(95)00001-8Get rights and content

Objective

To evaluate the experience with endometrial carcinoma in women 45 years or younger at the Royal Hospital for Women, Sydney, Australia.

Methods

We evaluated the clinical history, morphology, treatment, and follow-up of 17 premenopausal women 45 years or younger who had been diagnosed with endometrial cancer. All histopathology was reviewed.

Results

Sixteen patients received their primary treatment at the Royal Hospital for Women, and one was referred with recurrent disease. Synchronous ovarian malignancies were found in five of 17 cases (29.4%), compared with 11 of 237 (4.6%) women older than 45 (P <.001). Three other patients had secondary ovarian involvement. Five (29%) patients had stage III or IV disease. Thirteen (76.5%) women were alive with no evidence of disease 12–78 months after primary surgery; two were lost to follow-up, but had no evidence of disease at 21 and 29 months, respectively. Two women died of recurrent disease. All but two patients with stage IV disease receiving primary treatment at the Royal Hospital for Women were offered hormone replacement therapy on discharge from the hospital.

Conclusion

Ovarian and lymph node involvement were common in women 45 years and younger with endometrial cancer. Hormone replacement therapy did not appear to compromise survival.

References (25)

  • SilverbergSG et al.

    Endometrial cancer in women under 40 years of age

    Cancer

    (1977)
  • ConnollyPJ et al.

    Carcinoma of the endometrium III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma

    Obstet Gynecol

    (1982)
  • Cited by (179)

    • Uterine Cancer

      2019, Abeloff’s Clinical Oncology
    • Hormone-Responsive Cancers

      2019, Yen &amp; Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
    • Analysis of endometrial carcinoma in young women at a high-volume cancer center

      2017, International Journal of Surgery
      Citation Excerpt :

      Previous studies have reported the incidence of concurrent ovarian tumors among young women with EC in the range of 5–29% [5,15,16,18,21,34,35]. Gitsch et al. reported the highest rate of concurrent ovarian malignancy (29%) in the literature, but the number of patients in the study was extremely small (n = 17); in their research, occult metastasis in normal-appearing ovaries appeared was only evident in one patient [18]. In Walsh et al.’s study, the rate of coexisting ovarian malignancy in young women with EC was 25% [35].

    • Fertility-sparing management of endometrial cancer and atypical hyperplasia

      2017, Gynecologie Obstetrique Fertilite et Senologie
    View all citing articles on Scopus
    View full text